GlassScriptPhysician profile
Emma La Perla
NPI 1295223584
$1,360.32
in general payments reported to CMS, 2019-2025
15 companies · $640 in 2025
The $640 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $94.32 · 2023: $352 · 2024: $275 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,130.39 |
| Education | $135.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $216.83 | 2023-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $212.43 | 2023-2025 | Myfembree, Gemtesa |
| Sage Therapeutics, LLC | $200.53 | 2024-2025 | Zurzuvae |
| Abbvie INC. | $126.49 | 2023-2024 | |
| Exeltis, USA INC. | $120.86 | 2022-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $98.68 | 2022-2025 | |
| Exact Sciences Corporation | $86.58 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mayne Pharma Commercial LLC | $73.03 | 2024-2025 | |
| Coopersurgical, INC. | $57.98 | 2023-2025 | Paragard T 380a, Paragard T 380a |
| Pfizer INC. | $42.04 | 2023 | |
| Myovant Sciences INC. | $37.63 | 2022 | |
| Supernus Pharmaceuticals, INC. | $27.07 | 2025 | Qelbree |
| Agile Therapeutics, INC. | $22.70 | 2023 | Twirla |
| Therapeuticsmd, INC. | $19.26 | 2022 | |
| Organon LLC | $18.21 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma La Perla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.